BLU-285 (also known as Avapritinib, BLU285, BLU 285) is a potent and selective inhibitor of PDGFRα D842V and KIT Exon 17 mutants and is being developed as a highly targeted therapy for SM, a disorder of the mast cells in which a KIT Exon 17 mutation is the primary driver of disease.
ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets.
Blu-285, a Potent and Selective Inhibitor for Hematologic Malignancies with KIT Exon 17 Mutations.
 E.Evans, et al, Blood, 2015, 126(23), pp 568-568.
 No author listed, Cancer Discov., 2017, 7(2), pp 121-122.
Not listed as hazardous substance or mixture
NONH for all modes of transport
Sales restrictions may apply
1. Product Specification
2. Safety Data Sheet
Please inquire for pricing and availability of this product by writing email email@example.com.